

24th January, 2017

To,

1. National Stock Exchange of India
Exchange Plaza, 5th Floor, Plot no. C/1, G Block
Bandra Kurla Complex, Bandra (East)
Mumbai – 400 051
2. BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001

Sub.: Press Release on news appearing in media
(Scrip Codes: NSE – AJANTPHARM EQ & BSE –
AJANTPHARM 532331)

Dear Sir,

Further to our today's letter regarding clarification on news appearing in media, please find enclosed herewith Press release being issued by us in this regard, for your information and records.

Yours faithfully,



Gaurang Shah
Sr. GM – Legal & Company Secretary

Encl.: Press Release

Press Release

No import alert on us by US FDA

Mumbai, India – (24th January, 2017) - With this press release, we intend to clarify that there is no import alert by US FDA on our facility or any of our products approved by US FDA.

It appears that some unknown and unrelated entity/individual has sent some Sildenafil manufactured by Ajanta Pharma being sold in India or other emerging market to USA. We have no relations or connection to this dispatch of Sildenafil to USA. US authorities have seized this product as it is not approved by US FDA.

We once again clarify that there is no import alert on our facility or any of our products approved by US FDA and we continue to supply the products to US.

For more details visit www.ajantapharma.com.

For specific queries, contact:

Rajeev Agarwal Tel: +91 22 66061377 Email: rajeev.agarwal@ajantapharma.com

Safe Harbour Statement